Advertisement

Topics

Clinical Trials About "Mirata BioPharma, LLC" RSS

21:35 EDT 18th March 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Mirata BioPharma, LLC" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Mirata BioPharma, LLC" on BioPortfolio

We have published hundreds of Mirata BioPharma, LLC news stories on BioPortfolio along with dozens of Mirata BioPharma, LLC Clinical Trials and PubMed Articles about Mirata BioPharma, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mirata BioPharma, LLC Companies in our database. You can also find out about relevant Mirata BioPharma, LLC Drugs and Medications on this site too.

Showing "Mirata BioPharma" Clinical Trials, all 3

Relevant

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and efficacy (potential effects) of the new study drug.


Probably Relevant

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a major problem for effective long-term interventional success. This often results in repeated procedures to deal with recurrent stenosis (or restenosis) of the original targeted vessel. There is a substantial body of literature suggesting that local MYC protein production in the injured c...

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a major problem for effective long-term interventional success. This often results in repeated procedures to deal with recurrent stenosis (or restenosis) of the original targeted vessel. There is a substantial body of literature suggesting that local MYC protein production in the injured c...



More From BioPortfolio on "Mirata BioPharma, LLC"

Advertisement
Quick Search
Advertisement
Advertisement